Biotech Insider Buying: OvaScience Inc (NASDAQ:OVAS), BioTime (NYSEMKT:BTX), Insys Therapeutics (NASDAQ:INSY), Novavax (NASDAQ:NVAX), ImmuCell Corporation (NASDAQ:ICCC)

Technology Stocks News 9

Ovascience Inc (NASDAQ:OVAS) major shareholder Fund L.P. Longwood bought 100,000 shares of the company’s stock on the open market in a transaction dated Friday, March 7th. The stock was purchased at an average cost of $10.00 per share, for a total transaction of $1,000,000.00. OvaScience Inc (NASDAQ:OVAS) stock performance was -2.98% in last session and finished the day at $8.47. Traded volume was 69,618.00million shares in the last session and the average volume of the stock remained 73.64K shares. OvaScience Inc (NASDAQ:OVAS) insider ownership is 24.30%.

BioTime, Inc (NYSE:BTX) Director Broadwood Partners Lp bought 1,000,000 shares of the company’s stock in a transaction dated Monday, June 16th. The stock was purchased at an average cost of $2.50 per share, with a total value of $2,500,000.00. BioTime, Inc. (NYSEMKT:BTX) dropped -0.92 percent to $3.23 Thursday on volume of 478,911.00million shares. The intra-day range of the stock was $3.20 to $3.33. BioTime, Inc. (NYSEMKT:BTX) has a market capitalization of $233.04million.

Insys Therapeutics Inc (NASDAQ:INSY) Director John N. Kapoor acquired 5,000 shares of the stock on the open market in a transaction that occurred on Friday, June 13th. The stock was purchased at an average cost of $25.44 per share, with a total value of $127,200.00. Insys Therapeutics Inc (NASDAQ:INSY)’s stock on June 19, 2014 reported a increase of 5.30% to the closing price of $29.80. Its fifty two weeks range is $7.15 -$57.91. The total market capitalization recorded $1.02billion. The overall volume in the last trading session was 804,408.00million shares. In its share capital, INSY has 34.23million outstanding shares.

Novavax, Inc (NASDAQ:NVAX) SVP John Trizzino bought 16,500 shares of the stock on the open market in a transaction dated Monday, June 16th. The shares were purchased at an average cost of $4.51 per share, with a total value of $74,415.00. Following the completion of the acquisition, the senior vice president now directly owns 16,500 shares of the company’s stock, valued at approximately $74,415. On Thursday, shares of Novavax, Inc. (NASDAQ:NVAX) advanced 3.10% to close the day at $4.82. Company return on investment (ROI) is -25.50% and its monthly performance is recorded as 9.41%.  Novavax, Inc. (NASDAQ:NVAX) quarterly revenue growth is -2.72%.

ImmuCell Corporation (NASDAQ:ICCC) Director ROTHSCHILD JONATHAN E bought 5,901 shares of the stock on the open market in a transaction dated Monday, June 16th. The shares were purchased at an average cost of $4.566 per share, with a total value of $26,945.00. Following the completion of the acquisition, the Director now directly owns shares of the company’s stock, valued at approximately $510,536. ImmuCell Corporation (NASDAQ:ICCC) stock performance was 2.27% in last session and finished the day at $4.51. Traded volume was 199.00million shares in the last session and the average volume of the stock remained 2.59K shares. The beta of the stock remained -0.17. ImmuCell Corporation (NASDAQ:ICCC) insider ownership is 2.20%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone